carbidopa/levodopa / Generic mfg. - LARVOL DELTA

LEVODOPA/CARBIDOPA ASSOCIATED INFLAMMATORY COLITIS WITH POSITIVE RECHALLENGE: A CASE REPORT (UEGW 2026) - "Given concern for inflammatory bowel disease (IBD), she completed 6-week oral prednisolone taper. Budesonide was tapered over a total of 12 weeks. She remained clinically stable off budesonide & has remained off LD/CD without further relapse.Diagnosis: LD/CD associated inflammatory colitis."

Case report • Clinical • CNS Disorders • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Movement Disorders • Parkinson's Disease • CRP

PHYTOBEZOAR-INDUCED JEJUNAL TUBE IMPACTION IN PEG-J THERAPY: A RARE CAUSE OF DUODENAL PRESSURE ULCER (UEGW 2026) - "Clinical Case Summary: Continuous intestinal infusion of levodopa/carbidopa via PEG-J is a well-established therapy for advanced Parkinson's disease, but device-related complications may be subtle and easily overlooked due to nonspecific symptoms.We present a case of a 72-year-old woman with advanced Parkinson's disease treated with continuous levodopa infusion via PEG-J presented with one week of postprandial vomiting and worsening constipation...Distal bezoar formation may lead to tube impaction and pressure-related mucosal injury, including extensive ulcers. Early endoscopic recognition allows effective treatment and may prevent severe complications such as perforation or bleeding."

CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease • CRP

A Rare Case of Carbidopa-Levodopa Induced Colitis Complicated by Cytomegalovirus (ACG 2026) - "She was started on budesonide and mesalamine and had gradual improvement of diarrhea with resolution of hematochezia...She was treated with valganciclovir...(B) Random colon biopsies two months following carbidopa-levodopa discontinuation had crypt architectural distortion and focal mild inflammation, consistent with mucosal healing. H&E stained sections, 100x magnifications."

Clinical • CNS Disorders • Constipation • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Movement Disorders • Parkinson's Disease • Ulcerative Colitis • CRP

FLORA: A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients (clinicaltrials.gov) - P4 | N=58 | Recruiting | Sponsor: Navamedic AB

New P4 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Clinical course and biomarkers in patients with type 1 Gaucher disease and Parkinson's disease: A retrospective cohort study. (PubMed, Mol Genet Metab Rep) - "The majority (n = 9, 81.8%) were treated with levodopa/carbidopa with or without deep brain stimulation...Data from this single-center cohort demonstrate considerable variability in GD-PD among GD1 individuals and suggest that GD1 patients may have increased risk of GD-PD before the age of 50. Routine screening for PD in GD1 patients starting at age 40 may aid early diagnosis and close monitoring for initiation of PD-directed treatment."

Biomarker • Journal • Retrospective data • CNS Disorders • Gaucher Disease • Genetic Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 1 Gaucher Disease • GBA

Homocysteine as a Key Biomarker of Metabolic Stress During Foslevodopa/Foscarbidopa Infusion Therapy. (PubMed, Mov Disord) - No abstract available

Biomarker • Journal

Real-world neuropsychiatric safety profile of foslevodopa/foscarbidopa infusion in advanced Parkinson's disease. (PubMed, J Neurol) - "LDp/CDp infusion is well-tolerated. Although NAEs were more frequent than in pivotal trials, they were largely manageable. Frontal executive dysfunction emerged as a significant risk factor, suggesting specific frontal screening should be routine in candidacy evaluation for cognitively frail patients. Preventive strategies to reduce risk are proposed and discussed."

Journal • Real-world evidence • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease • Psychiatry

Infusion-Site Cutaneous Reactions During Continuous Subcutaneous Foslevodopa/Foscarbidopa Therapy: Real-World Experience and Management (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence

Effectiveness aNd use of fosleVOdopa-foscarbidopa in advanced Parkinson disease in real Life setting in France (ENVOL study): interim analysis (MDS Congress 2026) - No abstract available

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

The Sweet Smell of ON: Phantosmia During Motor Fluctuations After Initiation of Foslevodopa/Foscarbidopa Infusion Therapy (MDS Congress 2026) - No abstract available

CNS Disorders

From Vision to Reality: Nursing Driven Implementation, Policy, and Safety Framework for Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in a Tertiary Movement Disorder Centre (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Movement Disorders

First Reported Experience of Dual Therapy With Deep Brain Stimulation and Foslevodopa/Foscarbidopa Subcutaneous Infusion (MDS Congress 2026) - No abstract available

CNS Disorders

Psychosis in Parkinson’s Disease Patients Treated with Continuous Subcutaneous Foslevodopa/Foscarbidopa: A Real-World Observational Study. (MDS Congress 2026) - No abstract available

Clinical • Observational data • Real-world • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Pharmacoscintigraphic Evaluation and Safety of a Novel, Dual-pulse, Delayed-release carbidopa/levodopa Tablet for Bedtime Dosing (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders

Serum Zinc Reduction During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease (MDS Congress 2026) - No abstract available

CNS Disorders • Movement Disorders • Parkinson's Disease

Beyond Motor Fluctuations: Non-Motor and Quality-Of-Life Outcomes with Subcutaneous Foslevodopa/Foscarbidopa Infusion in Real-World Practice (MDS Congress 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • CNS Disorders

Real-world variability in dosing of continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease: evidence from a single-center cohort (MDS Congress 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Inpatient Titration Protocol and Practical Implementation of Continuous Subcutaneous Foslevodopa/Foscarbidopa: Lessons from 28 Consecutive Cases (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders

Impact of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion on Neuropsychiatric Symptoms in Clinical Practice: A Multicenter Study (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Psychiatry

A Case Report: Optimising Motor and Non-Motor Control in Advanced Parkinson’s Disease: The Role of Foslevodopa/Foscarbidopa After Deep Brain Stimulation (MDS Congress 2026) - No abstract available

Case report • Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Real-World Impact of “Off” Time Reduction with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of the ROSSINI Study (MDS Congress 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Impact of foslevodopa/foscarbidopa infusion on autonomic symptoms in advanced Parkinson’s Disease (MDS Congress 2026) - No abstract available

Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Discontinuation Patterns and Predictive Factors in Continuous Subcutaneous Foslevodopa/Foscarbidopa (FLC/FCD) Therapy: Insights from Early Clinical Experience (MDS Congress 2026) - No abstract available

Biomarker • Clinical • CNS Disorders

Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in Advanced Parkinson’s Disease: Results from a Prospective Real-world Study (MDS Congress 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Single centre experience with subcutaneous foslevodopa/foscarbidopa for GBA Parkinson's disease (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease